Introduction
Scope
Novartis' Gleevec is widely credited as being one of the most important drug launches of all time, having revolutionised the treatment of chronic myeloid leukaemia (CML) and transformed what was a terminal disease into a chronic one. As a result, the drug has reaped significant commercial benefits for Novartis, generating global sales of .7 billion in 2012.
However, the CML market has become increasingly crowded, following the launch of second-generation therapies – Novartis' own Tasigna and Bristol-Myers Squibb's Sprycel – and the recently launched third-generation therapy Iclusig, which is marketed by Ariad Pharmaceuticals.
Paragraph>Most usage of second- and third-generation therapies currently occurs in patients who do not gain sufficient benefit from Gleevec (which accounts for approximately 85 percent of first-line usage – which in turn accounts for around 82 percent of market share). However, some analysts and industry commentators believe that the more potent second- and third-generation products have an opportunity to be used more widely – built around a thesis that earlier use with these products produces a deeper and a faster response, which could potentially prolong overall survival (Novartis is seeking to demonstrate this benefit for Tasigna versus Gleevec).
However, there would appear to be a limited window of maximum commercial opportunity for the second- and third-generation CML therapies to displace Gleevec, given that Novartis' first-generation product will most likely face US patent expiry in 2015.
Puchase Reasons
Set against this backdrop of uncertainty, this week's Physician Views poll will ask US-based oncologists to share their opinions towards the CML treatment paradigm. Specifically the poll will ask...
Table of Contents
for Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
Additional Details
Publisher
FirstWord Pharma
Publisher Information
Reference
47 |
Report Format

Related Reports
Title | Date Published | Price from | More Details |
---|---|---|---|
SAVE 15% today! Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market? ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi... | 01 Aug 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
SAVE 15% today! Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies? ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood... | 01 Aug 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
SAVE 15% today! Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD? ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis... | 01 Aug 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
SAVE 15% today! Physician Views: Which diabetes company does the best marketing job? What is key for companies launching products? ScopeThe importance of marketing is increasingly coming to the fore as diabetes-focused companies ba... | 01 Aug 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
SAVE 15% today! Physician Views: Post ADA view on key diabetes market developments ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab... | 01 Jul 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
SAVE 15% today! Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready? ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re... | 01 Jul 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
SAVE 15% today! Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor? ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti... | 01 Jul 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
SAVE 15% today! Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ... | 01 Jul 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
SAVE 15% today! Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture... | 01 Jun 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
SAVE 15% today! Surveying Physician Uptake of Mobile Devices and Apps IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo... | 01 Oct 2012 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
This report is published by FirstWord Pharma
Download Free Report Summary PDF

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Ordering Information
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types

Buy now using our secure payment system.